Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter

Human Gene Therapy

Volumn 19, Issue 9, 2008, Pages 951-957

  Kim, Seung Hoo ^a   Chung, Hye Kyung ^a   Kang, Joo Hyun ^b   Kim, Kwang Il ^a   Jeon, Yong Hyun ^a   Jin, Yong Nan ^a   Yun, Chae Ok ^c   Chung, June Key ^a,d  

^a Seoul National University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RETROVIRUS VECTOR; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG UPTAKE; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROMOTER REGION; SCINTIGRAPHY;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; PLASMIDS; PROMOTER REGIONS, GENETIC; RETROVIRIDAE; SYMPORTERS; TELOMERASE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 51849160271     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.030     Document Type: Article

References (27)

1. Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham, M.A., and Reddel, R.R. (1997). Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 11, 1198-1199.
2. Cerni, C. (2000). Telomeres, telomerase, and Myc: An update. Mutat. Res. 462, 31-47.
3. Chen, L., Altmann, A., Mier, W., Eskerski, H., Leotta, K., Guo, L., Zhu, R., and Haberkorn, U. (2006). Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J. Nucl. Med. 47, 854-862.
4. Chung, J.K. (2002). Sodium/iodide symporter: Its role in nuclear medicine. J. Nucl. Med. 43, 1188-1200.
5. Dadachova, E., Nguyen, A., Lin, E.Y., Gnatovskiy, L., Lu, P., and Pollard, J.W. (2005). Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl. Med. Biol. 32, 695-700.
6. Dai, G., Levy, O., and Carrasco, N. (1996). Cloning and characterization of the thyroid iodide transporter. Nature 379, 458-460.
7. Gellert, G.C., Jackson, S.R., Dikmen, Z.G., Wright, W.E., and Shay, J.W. (2005). Telomerase as a therapeutic target in cancer. Drug Discov. Today 2, 159-164.
8. Groot-Wassink, T., Aboagye, E.O., Wang, Y., Lemoine, N.R., Keith, W.N., and Vassaux, G. (2004). Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res. 64, 4906-4911.
9. Hernandez-Alcoceba, R., Sangro, B., and Prieto, J. (2006). Gene therapy of liver cancer. World J. Gastroenterol. 12, 6085-6097.
10. Huang, M., Batra, R.K., Kogai, T., Lin, Y.Q., Hershman, J.M., Lichtenstein, A., Sharma, S., Zhu, L.X., Brent, G.A., and Dubinett, S.M. (2001). Ectopic expression of the thyroperoxidase gene augments radioiodine uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 8, 612-618.
11. Kang, J.H., Chung, J.K., Lee, Y.J., Shin, J.H., Jeong, J.M., Lee, D.S., and Lee, M.C. (2004). Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J. Nucl. Med. 45, 1571-1576.
12. Keith, W.N., Evans, T.R.J., and Glasspool, R.M. (2001). Telomerase and cancer: Time to move from a promising target to a clinical reality. J. Pathol. 195, 404-414.
13. Kim, E., Kim, J.H., Shin, H.Y., Lee, H., Yang, J.M., Kim, J, Sohn, J.H., Kim, H., and Yun, C.O. (2003). Ad-mTERT-Δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 14, 1415-1428.
14. Kogai, T., Taki, K., and Brent, G.A. (2006). Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer. 13, 797-826.
15. Komata, T., Kondo, Y., Kanzawa, T., Hirohata, S., Koga, S., Sumiyoshi, H., Srinivasula, S.M., Barna, B.P., Germano, I.M., Takakura, M., Inoue, M., Alnemri, E.S., Shay, J.W., Kyo, S., and Kondo, S. (2001). Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61, 5796-5802.
16. Kontani, K., Taguchi, O., Ozaki, Y., Hanaoka, J., Tezuka, N., Sawai, S., Inoue, S., Fujino, S., Maeda, T., Itoh, Y., Ogasawara, K., Sato, H., Ohkubo, I., and Kudo, T. (2002). Novel vaccination protocol consisting of injecting MUC1 DNA and non-primed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther. 9, 330-337.
17. Kyo, S., Takakura, M., Taira, T, Kanaya, T., Itoh, H., Yutsudo, M., Ariga, H., and Inoue, M. (2000). Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 28, 669-677.
18. Lin, T., Huang, X., Gu, J., Zhang, L., Roth, J.A., Xiong, M., Curley, S.A., Yu, Y., Hunt, K.K., and Fang, B. (2002). Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21, 8020-8028.
19. Liu, X., Gu, J., and Shi, W. (2005). Targeting gene-virotherapy for cancer. Acta Biochim. Biophys. Sin. (Shanghai) 37, 581-587.
20. Meyerson, M., Counter, C.M., Eaton, E.N., Ellisen, L.W., Steiner, P., Caddle, S.D., Ziaugra, L., Beijersbergen, R.L., Davidoff, M.J., Liu, Q., Bacchetti, S., Haber, D.A., and Weinberg, R.A. (1997). hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-795.
21. Plumb, J.A., Bilsland, A., Kakani, R., Zhao, J., Glasspool, R.M., Knox, R.J., Evans, T.R., and Keith, W.N. (2001). Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20, 7797-7803.
22. Scheel, C., and Poremba, C. (2002). Telomere lengthening in telomerase-negative cells: The ends are coming together. Virchows Arch. 440, 573-582.
23. Spitzweg, C., Heufelder, A.E., and Morris, J.C. (2000). Thyroid iodine transport. Thyroid 10, 321-330.
24. Spitzweg, C., Harrington, K.J., Pinke, L.A., Vile, R.G., and Morris, J.C. (2001). The sodium iodide symporter and its potential role in cancer therapy. J. Clin. Endocrinol. Metab. 86, 3327-3335.
25. Ulaner, G.A. (2004). Telomere maintenance in clinical medicine. Am. J. Med. 117, 262-269.
26. Wang, J., Xie, L.Y., Allan, S., Beach, D., and Hannon, G.J. (1998). Myc activates telomerase. Genes Dev. 12, 1769-1774.
27. Wenzel, A., Upadhyay, G., Schmitt, T.L., and Loos, U. (2003). Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS. Mol. Cell. Endocrinol. 213, 99-108.